Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Companies › LQDA

Liquidia

LQDA Rare disease Lead: Approved 3 Biotech Distilled articles ↓ 17 filings & releases ↓ Cash $284M (Jun 30, 2026) ↓ 3 verdicts ↓
CardiovascularImmunologyRespiratory Small Molecule

Market cap $3.97B 89.5M shares (10-Q, Jul 29, 2026) × $44.40 close Nov 6, 2026

Most recent annual filing: 2026-03-05

Catalyst timeline

10 trackedQuarter catalyst calendar →
  1. YUTREPIA SPRINT trial start2H 2026YUTREPIA SPRINT trial start, 2H 2026, routine
  2. UTHR soft-mist inhaler FDA approval2027UTHR soft-mist inhaler FDA approval, 2027, material
  3. YUTREPIA SSc-RP readoutFeb 2027YUTREPIA SSc-RP readout, Feb 2027, notable
  4. Tyvaso UTHR FDA decisionApr 2027Tyvaso UTHR FDA decision, Apr 2027, material
  5. Settlement payments corporate updateApr 30, 2027Settlement payments corporate update, Apr 30, 2027, notable
  6. '782 patent expiryMay 14, 2027'782 patent expiry, May 14, 2027, routine
  7. Ralinepag UTHR PDUFA dateJun 24, 2027Ralinepag UTHR PDUFA date, Jun 24, 2027, material
  8. Tyvaso PPF topline2H 2027Tyvaso PPF topline, 2H 2027, material
  9. YUTREPIA trial start2H 2027YUTREPIA trial start, 2H 2027, routine
  10. YUTREPIA corporate updateMay 23, 2028YUTREPIA corporate update, May 23, 2028, routine

Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.

Pipeline (9 active programs)

Technology platforms

PRINT

Particle Replication In Nonwetting Templates — proprietary technology enabling precise, uniform drug particles by size, shape, and composition; engineered for enhanced pulmonary deposition via oral inhalation; used to develop treprostinil inhalation powder for pulmonary hypertension and other respiratory/vascular indications

PRINT · University of North Carolina at Chapel Hill

Particle Replication In Non-wetting Templates (PRINT) — proprietary particle engineering platform enabling precise production of uniform drug particles with controlled size, shape, and chemical composition; applied to inhaled drug formulations for cardiopulmonary diseases including PAH and PH-ILD; licensed non-exclusively to GSK for preclinical research and exclusively to Alcon (via Aerie) for ophthalmic therapies

Discontinued (1)

Capital (as filed)

Cash
$284M cash and cash equivalents · Jun 30, 2026 (10-Q)
Operating cash flow
$80.2M quarter Mar 31, 2026 → Jun 30, 2026, year-to-date difference (10-Q)
As stated in coverage
$396M cash per the update of Oct 13, 2026 — the company's own words as read there, not the filed figure

Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 7, 2026.

Biotech Distilled coverage (3)

Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.

Verdict history (3 calls)

Every verdict Biotech Distilled has published on Liquidia, oldest first — the full history, never a selection. How calls are scored: the track record.

  1. 2026-10-01 Watch Liquidia Corporation (LQDA) - Scientific Deep Dive for YUTREPIA, L606 and Pipeline Products YUTREPIA's PAH business is real and profitable at a single-digit multiple, but the court has not yet defined the remedy scope, making any purchase a bet on how a judge will word an order.
  2. 2026-10-13 Speculative buy speculative UPDATE: Liquidia (LQDA) - Peace, at $380.7 Million The settlement removes the remedy binary, trade-secret injunction risk, and open damages tab, delivering the substance of the re-entry trigger, justifying a small starter position sized for the November Q3 call.
  3. 2026-10-15 Speculative buy speculative UPDATE: Liquidia (LQDA) - The Fine Print Behind the Peace Speculative Buy maintained despite the covenant floor tripling and a CEO-linked entity being paid, as PH-ILD sales continue until FDA relabels and L606 retains an invalidity defense, though after a 26.6% rally the entry is less forgiving.

Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.

Filings & releases (17)

SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Sep 30, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →

6 more filings (13G holder notices, S-8, proxy material, SEC correspondence …)